Storia in 2 fonti

U.S. FDA issues warning letter to Aurobindo Pharma’s subsidiary Eugia Pharma

Aurobindo Pharma's subsidiary Eugia Pharma receives a U.S. FDA warning letter following previous compliance issues at its Hyderabad facility.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindu.comStai leggendo3 g fa

Aurobindo Pharma's subsidiary Eugia Pharma receives a U.S. FDA warning letter following previous compliance issues at its Hyderabad facility.

Aurobindo Pharma's Eugia Pharma unit in Telangana receives a USFDA warning letter after recent inspections, but supply remains unaffected.